Microdosing GLP-1s: What It Means, Who It's For, and What the Evidence Says

Microdosing a GLP-1 means using a smaller-than-standard dose of a GLP-1 receptor agonist — most often compounded semaglutide or compounded tirzepatide prepared by a licensed 503A pharmacy. People explore microdosing to ease side effects, support modest weight or metabolic goals, or maintain results after weight loss. Sub-label dosing is off-label, has not been tested in large clinical trials, and should only be done under clinician supervision.

What does microdosing a GLP-1 actually mean?

Microdosing a GLP-1 is the practice of taking a dose smaller than the lowest FDA-approved starting dose of a GLP-1 receptor agonist — a drug class that includes semaglutide and the GIP/GLP-1 dual agonist tirzepatide. It is not an official medical term; it grew out of patient communities and telehealth practice, not from drug labels. Because it sits outside approved labeling, microdosing is off-label and is currently being studied rather than formally approved at these doses.

How microdosing differs from standard FDA-approved dosing

Standard GLP-1 dosing follows a titration schedule. For semaglutide approved for weight management, patients start at 0.25 mg weekly and step up every four weeks toward a maintenance dose of 2.4 mg weekly [1]. Tirzepatide approved for weight management starts at 2.5 mg weekly and titrates up to 5, 10, or 15 mg [2]. Microdosing pauses, slows, or shrinks those steps — for example, staying near 0.1–0.25 mg of semaglutide instead of climbing.

Why the practice has grown in popularity

Three trends pushed microdosing into the spotlight. First, many patients struggle with nausea, constipation, and fatigue at standard doses [4]. Second, monthly costs for brand-name GLP-1s can exceed $1,000 without insurance [5]. Third, periods on the FDA drug shortage list opened a window for compounded versions from 503A pharmacies, which can be prepared at flexible concentrations under a valid prescription [10].

Which GLP-1 medications are people microdosing?

Compounded semaglutide (and brand-name Ozempic, Wegovy)

Semaglutide is a GLP-1 receptor agonist that is FDA-approved as Ozempic for type 2 diabetes and Wegovy for chronic weight management [1]. The same molecule is also available as compounded semaglutide through licensed 503A pharmacies under an individual prescription. Compounded semaglutide is not itself FDA-approved as a finished drug; it is a patient-specific preparation permitted under federal compounding law when clinically appropriate [10]. Because compounded versions can be prepared at non-standard concentrations, they are the most common form used for clinician-supervised microdosing. Our compounded semaglutide guide walks through the details.

Compounded tirzepatide (and brand-name Mounjaro, Zepbound)

Tirzepatide is a GIP/GLP-1 dual agonist — it activates two gut hormone receptors instead of one [2]. It is FDA-approved as Mounjaro (diabetes) and Zepbound (weight management) and is also dispensed as compounded tirzepatide by licensed 503A pharmacies. The compounded form is not an FDA-approved finished drug; it is prepared per prescription under federal compounding rules [10]. In the SURMOUNT-1 trial, tirzepatide at full doses produced average weight loss of about 20% over 72 weeks [6], though GI side effects were common during titration [2]. Microdoses have not been tested at population level. Compounded oral tirzepatide tablets are also being studied as a needle-free option; see our oral tirzepatide tablets overview. Oral tablets are not an FDA-approved formulation.

Liraglutide (Saxenda, Victoza)

Liraglutide is an older, daily-injection GLP-1, FDA-approved as Saxenda for weight management and Victoza for diabetes [7]. It carries the same boxed warning and GI side-effect profile as other GLP-1s [7]. It is less commonly microdosed because its shorter half-life and daily dosing already allow finer-grained titration.

What doses are typically used when microdosing?

Common microdose ranges reported in clinical practice

There is no official microdosing protocol, and sub-label doses have not been studied in large trials. The ranges below reflect what is commonly described in telehealth practice and patient communities — they are for education only and are not prescriptions or dosing recommendations. Typical starting doses always come from a licensed clinician after a full evaluation that weighs benefits against side effects and contraindications.

Why exact dosing must come from a clinician, not the internet

Injectable medications are not safe to self-adjust. Drawing a smaller dose from a multi-dose vial requires accurate measurement, sterile technique, and a clear understanding of concentration. Oral tablets also need clinician-set strengths and schedules. A licensed clinician should match your dose to your medical history, goals, and side-effect profile — and adjust it over time.

What are the potential benefits of microdosing?

Patient-reported benefits are real, but most data come from full-dose trials and observational reports — sub-label doses have not been systematically studied. Any benefit must be weighed against side effects (nausea, constipation, vomiting) and serious risks (pancreatitis, gallbladder disease, the boxed warning for medullary thyroid carcinoma) that apply at any dose [1][2]. Benefits below are not guaranteed, and individual results vary.

Fewer GI side effects

Nausea, constipation, and reflux are dose-dependent for GLP-1s [4]. In clinical trials, these side effects were most common during titration steps. A lower dose may reduce these symptoms, but it can also reduce the medication's effect on appetite and weight, and it does not eliminate the risk of more serious adverse events. Our guide to managing GLP-1 side effects covers strategies that apply at any dose.

Lower monthly cost

A smaller dose can stretch a vial supply further. For compounded GLP-1s, where prescriptions are often priced per milligram, a lower dose can reduce monthly cost — though this varies by pharmacy and plan, and cost should not be the only factor in a dosing decision.

Maintenance after reaching a goal weight

The STEP-4 trial showed that stopping semaglutide led to significant weight regain over the following year [8]. Some clinicians use a lower maintenance dose to help patients hold their results with fewer side effects, though long-term outcomes at sub-label doses are not yet well studied and the same contraindications apply. See our piece on GLP-1 maintenance dosing for more.

Metabolic and appetite support

At standard doses, GLP-1s lower fasting glucose, improve insulin sensitivity, and reduce appetite signaling [3]. The SELECT trial showed that semaglutide reduced major cardiovascular events by about 20% in adults with overweight or obesity and established heart disease — at standard, not sub-label, doses [9]. Whether these effects are preserved at microdoses is not established, and microdosing should not be assumed to provide the cardiovascular benefits seen in trials.

What are the risks and limitations?

Limited clinical trial evidence at sub-label doses

Phase 3 trials for semaglutide and tirzepatide tested specific dose schedules. There are no large randomized trials of 0.1 mg semaglutide weekly or 1 mg tirzepatide weekly. That means efficacy, long-term safety, and effects on cardiovascular outcomes at these doses are not well established.

Risk of underdosing and weight regain

If the dose is too small to meaningfully affect appetite, progress may be slow or absent. For patients in maintenance, an underdose can allow gradual weight regain over months.

Safety concerns at any dose

Common side effects of all GLP-1s include nausea, vomiting, diarrhea, and constipation [1][2]. Rare but serious risks include pancreatitis, gallbladder disease, and — based on rodent studies — a boxed warning for medullary thyroid carcinoma [1]. These risks do not disappear at lower doses. GLP-1s are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and in people who are pregnant or trying to become pregnant [1]. Self-adjusting an injectable prescription medication adds further risks of dosing error, contamination, and unsafe technique.

Who might be a candidate for microdosing a GLP-1?

Whether microdosing is appropriate depends on your medical history, goals, and how you respond to the medication. The categories below describe situations clinicians may consider — they are not eligibility criteria, and only a licensed clinician can determine fit after weighing the side-effect and contraindication profile described above.

• People sensitive to side effects who could not tolerate standard titration.
• Patients in a maintenance phase who have reached a goal weight on a full dose and want to hold it with less medication.
• Patients managing cost when insurance does not cover brand-name GLP-1s.
• People who prefer to avoid injections and want to discuss compounded oral tirzepatide tablets with a clinician.

Microdosing is generally not appropriate for people who have not had a clinical evaluation, who have contraindications to GLP-1 therapy, or who are pregnant or trying to become pregnant [1].

How do you get a microdose GLP-1 prescription?

Telehealth evaluation and eligibility

Any GLP-1 prescription — micro or standard dose — starts with a clinical evaluation. A licensed clinician reviews your medical history, current medications, labs, and goals to decide whether a GLP-1 is appropriate and at what dose. This can be done in person or through telehealth.

Compounded vs branded GLP-1 options

Branded medications come in fixed-dose pens or pre-filled devices, which makes precise microdosing harder. Compounded semaglutide and compounded tirzepatide are prepared by licensed 503A compounding pharmacies based on an individual prescription, which can allow non-standard concentrations [10]. Compounded GLP-1s are permitted when prepared by a licensed pharmacy under a valid prescription and have commonly been used during FDA shortages or for patient-specific clinical needs. They are not FDA-approved finished drugs. Our overview of the 503A compounding pharmacy model explains how this works.

Working with a licensed telehealth provider

Several licensed telehealth providers offer GLP-1 evaluations. Chia Health is one such option — it connects patients with licensed clinicians and 503A pharmacies for compounded semaglutide and compounded tirzepatide, including oral tirzepatide tablets where clinically appropriate. A clinician — not an algorithm or marketing page — sets the starting dose and adjusts it over time. Eligibility depends on a clinical evaluation, and individual results vary. For more on how the two main injections compare, see our guide to tirzepatide vs semaglutide.

Microdose vs standard dose: a side-by-side comparison

Frequently asked questions

Keep reading

GLP-1 & Weight Loss

Cheapest Weight Loss Injections Online in 2026: Price Comparison and What to Know Before You Buy

Weight Loss

Weight Loss Drugs Online: How Telehealth Prescribing Works in 2026

GLP-1 Medications

GLP-1 Side Effects: What to Expect and How to Manage Them